Want to see TXMD full AI Analyst Report?
TXMD Stock Chart & Stats
$1.68
-$0.07(-6.14%)
At close: 4:00 PM EST
$1.68
-$0.07(-6.14%)
Day’s Range― - ―
52-Week Range$0.99 - $2.95
Previous CloseN/A
Volume92.69K
Average Volume (3M)310.58K
Market Cap
$24.42M
Enterprise Value$20.92
Total Cash (Recent Filing)$8.42M
Total Debt (Recent Filing)$5.83M
Price to Earnings (P/E)137.0
Beta1.06
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding11,574,362
10 Day Avg. Volume897,126
30 Day Avg. Volume310,579
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)0.70
Price to Sales (P/S)6.24
P/FCF Ratio7.78
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.17
Revenue Forecast (FY)$9.30M
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthTherapeuticsMD’s low debt-to-equity (~0.18 TTM) and positive equity reduce solvency risk and provide durable financial flexibility. A conservatively financed balance sheet supports continued R&D, licensing monetization, or opportunistic M&A without forcing distressed financing even if operating results remain uneven.
Improving Cash GenerationPositive and growing free cash flow provides an ongoing internal funding source for operations, licensing obligations, and strategic actions. Improved cash generation reduces reliance on external capital, lengthens runway for executing strategy, and supports a more sustainable capital allocation profile over coming quarters.
High Gross Margins; Profit SwingA ~66% gross margin signals strong product economics and pricing power in core women’s health franchises. Coupled with a return to slight net income, this suggests cost discipline and margin resilience that can support eventual operating leverage as revenues stabilize or grow.
Bears Say
Declining RevenueA 13% TTM revenue decline is a structural concern: shrinking top-line limits scalability, puts pressure on fixed-cost absorption, and undermines sustainable margin improvement. Continued revenue contraction would erode the recent cash-flow gains and constrain reinvestment or strategic optionality.
Negative Operating MarginsPersistently negative operating and EBITDA margins indicate core operations are not yet self-sustaining. Even with net income improvements from non-operating items or one-offs, weak operating profitability limits durable earnings power and increases dependence on licensing, cost cuts, or strategic transactions to reach structural profitability.
Strategic UncertaintyOngoing evaluation of M&A, asset sales or other alternatives creates long-duration uncertainty about capital allocation and business direction. Lack of timetable risks management distraction, inconsistent reinvestment, and unpredictable outcomes that can materially alter the company’s structural growth and cash-generation profile.
TherapeuticsMD News
TXMD FAQ
What was TherapeuticsMD’s price range in the past 12 months?
TherapeuticsMD lowest stock price was $0.99 and its highest was $2.95 in the past 12 months.
What is TherapeuticsMD’s market cap?
TherapeuticsMD’s market cap is $24.42M.
When is TherapeuticsMD’s upcoming earnings report date?
TherapeuticsMD’s upcoming earnings report date is Aug 17, 2026 which is in 26 days.
How were TherapeuticsMD’s earnings last quarter?
TherapeuticsMD released its earnings results on May 12, 2026. The company reported $0.008 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is TherapeuticsMD overvalued?
According to Wall Street analysts TherapeuticsMD’s price is currently Overvalued.
Does TherapeuticsMD pay dividends?
TherapeuticsMD does not currently pay dividends.
What is TherapeuticsMD’s EPS estimate?
TherapeuticsMD’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TherapeuticsMD have?
TherapeuticsMD has 11,574,362 shares outstanding.
What happened to TherapeuticsMD’s price movement after its last earnings report?
TherapeuticsMD reported an EPS of $0.008 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.59%.
Which hedge fund is a major shareholder of TherapeuticsMD?
Currently, no hedge funds are holding shares in TXMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TherapeuticsMD
TherapeuticsMD, Inc. is a U.S.-based pharmaceutical company dedicated to women's health. Its marketed portfolio includes IMVEXXY, prescribed for moderate to severe dyspareunia; BIJUVA, a bio-identical hormone replacement therapy combining 17ß-estradiol and progesterone, used to alleviate moderate to severe vasomotor symptoms; and ANNOVERA, an innovative vaginal ring designed for contraception. In its developmental pipeline, TherapeuticsMD is advancing several preclinical candidates: TX-005HR, a transdermal cream containing only progesterone; TX-006HR, another transdermal cream formulated with both estradiol and progesterone; TX-007HR and TX-008HR, both experimental transdermal patches; and TX-009HR, an oral formulation of progesterone and estradiol. Beyond its core pharmaceutical offerings, the company produces and distributes both branded and generic prescription prenatal vitamins, notably under the vitaTrue, vitaPearl, vitaMedMD, and BocaGreenMD Prena1 labels. Its prescription medications and prenatal vitamin lines reach consumers through established channels, including wholesale and retail pharmacy distributors. Established in 2008, TherapeuticsMD, Inc. maintains its corporate headquarters in Boca Raton, Florida.
Technical Analysis
Ownership Overview
1.56% Insiders
4.11% Mutual Funds
<0.01% Other Institutional Investors
91.18% Public Companies and
Individual Investors